These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12538800)

  • 41. Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
    Brusa L; Pierantozzi M; Bassi A; Fedele E; Lunardi G; Giacomini P; Stanzione P
    Neurol Sci; 2004 Jun; 25(2):53-6. PubMed ID: 15221622
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacodynamic response of entacapone in rats after administration of entacapone formulations and prodrugs with varying bioavailabilities.
    Forsberg M; Savolainen J; Järvinen T; Leppänen J; Gynther J; Männistö PT
    Pharmacol Toxicol; 2002 Jun; 90(6):327-32. PubMed ID: 12403054
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.
    Nissinen E; Lindén IB; Schultz E; Pohto P
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):262-6. PubMed ID: 1407012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
    Arnold G; Kupsch A
    Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis.
    Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
    Fischer JJ; Michaelis S; Schrey AK; Graebner OG; Glinski M; Dreger M; Kroll F; Koester H
    Toxicol Sci; 2010 Jan; 113(1):243-53. PubMed ID: 19783845
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials.
    Kieburtz K; Hubble J
    Neurology; 2000; 55(11 Suppl 4):S42-5; discussion S46-50. PubMed ID: 11147509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.
    Dingemanse J; Jorga K; Zürcher G; Schmitt M; Sedek G; Da Prada M; Van Brummelen P
    Br J Clin Pharmacol; 1995 Sep; 40(3):253-62. PubMed ID: 8527287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
    Männistö PT; Tuomainen P; Tuominen RK
    Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
    Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
    Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
    Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
    Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
    Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT
    J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
    Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
    Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone.
    Vieira-Coelho MA; Soares-da-Silva P
    Br J Pharmacol; 1996 Feb; 117(3):516-520. PubMed ID: 8821542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.
    Lees AJ
    CNS Neurosci Ther; 2008; 14(1):83-93. PubMed ID: 18482101
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.
    Dingemanse J; Jorga K; Zürcher G; Fotteler B; Sedek G; Nielsen T; van Brummelen P
    Eur J Clin Pharmacol; 1996; 50(1-2):47-55. PubMed ID: 8739811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors.
    Pinheiro SD; Serrão MP; Silva T; Borges F; Soares-da-Silva P
    Eur J Pharmacol; 2019 Mar; 847():53-60. PubMed ID: 30685433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats.
    Li YH; Wirth T; Huotari M; Laitinen K; MacDonald E; Männistö PT
    Eur J Pharmacol; 1998 Sep; 356(2-3):127-37. PubMed ID: 9774242
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease.
    Entacapone to Tolcapone Switch Study Investigators
    Mov Disord; 2007 Jan; 22(1):14-9. PubMed ID: 17089403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.